Biological medication in atopic dermatitis

References

• Gooderham MJ, Hong -HC-H, Eshtiaghi O, et al. Dupilumab: a review of its use in the treatment of atopic dermatitis. J Am Acad Dermatol. 2018;78(Suppl 1):S28–36.
   PubMedGoogle Scholar
• Vangipuram R, Tyring SK. Dupilumab for moderate-to-severe atopic dermatitis. Skin Therapy Lett. 2017;22:1–4.
   PubMedGoogle Scholar
• Sanchez-Ramon S, Eguiluz-Gracia I, Rodriguez-Mazariego ME, et al. Sequential combined therapy with omalizumab and rituximab a new approach to severe atopic dermatitis. J Investig Allergol Clin Immunol. 2013;23:190–196.
   PubMed Web of Science ®Google Scholar
• Seegraber M, Srour J, Walter A, et al. Dupilumab for treatment of atopic dermatitis. Expert Rev Clin Pharmacol. 2018;11:467–474.
   PubMed Web of Science ®Google Scholar
• Rehal B, Armstrong A. Health outcome measures in atopic dermatitis: a systematic review of trends in disease severity and Quality-of-Life instruments 1985–2010. PLoS One. 2011;6:e17520.
   PubMed Web of Science ®Google Scholar
• De Bruin-Weller M, Thaci D, Smith CH, et al. Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical trial (LIBERTY AD CAFÉ). Br J Dermatol. 2018;178:1083–1101.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Paller AS, Siegfried EC, et al. Efficacy and safety of dupilumab in adolescents with uncontrolled moderate to severe atopic dermatitis: a phase 3 randomized clinical trial. JAMA Dermatol. 2020;156:44–56.
   PubMed Web of Science ®Google Scholar
• Paller AS, Siegfried EC, Thaci D, et al. Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: a randomized, double-blinded, placebo-controlled phase 3 trial. J Am Acad Dermatol. 2020;83:1282–1293.
   PubMed Web of Science ®Google Scholar
• Boguniewicz M, Alexis AF, Beck LA, et al. Expert perspectives on management of moderate-to-severe atopic dermatitis: a multidisciplinary consensus addressing current and emerging therapies. J Allergy Clin Immunol Pract. 2017;5:1519–1531.
   PubMed Web of Science ®Google Scholar
• Furue M, Yamamura K, Kido-Nakahara M, et al. Emerging role of interleukin-31 and interleukin-31 receptor in pruritus in atopic dermatitis. Allergy. 2018;73:29–36.
   PubMed Web of Science ®Google Scholar
• Dubin C, Duca ED, Guttman-Tassky E. The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. Expert Rev Clin Immunol. 2021;17:835–852.
   PubMed Web of Science ®Google Scholar
• Renert-Yuval Y, Duca ED, Pavel AB, et al. The molecular features of normal and atopic dermatitis skin in infants, children, adolescents, and adults. J Allergy Clin Immunol. 2021;148:148–163. Chipalkatti N, Lee N, Zancanaro P, Dumont N, Kachuk C, Rosmarin D. A retrospective review of dupilumab for atopic dermatitis patients with allergic contact dermatitis. J Am Acad Dermatol. 2019;80:1166–1167.
   PubMed Web of Science ®Google Scholar
• Siegfried EC, Igelman S, Jaworsk JC, et al. Use of dupilumab in pediatric atopic dermatitis: Access, dosing, and implications for managing severe atopic dermatitis. Pediatr Dermatol. 2019;36:172–176.
   PubMed Web of Science ®Google Scholar
• Hamilton JD, Ungar B, Guttman-Yassky E. Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy. 2015;7:1043–1058.
   PubMed Web of Science ®Google Scholar
• Kraft M, Worm M. Dupilumab in the treatment of moderate-to-severe atopic dermatitis. Expert Rev Clin Immunol. 2017;13:301–310.
   PubMed Web of Science ®Google Scholar
• Simpson EL, Bieber T, Guttman-Yassky E, et al. Two phase 3 trials of dupilumab versus placebo in atopic dermatitis. N Eng J Med. 2016;375:2335–2348.
   PubMed Web of Science ®Google Scholar
• Blauvelt A, de Bruin-weller M, Gooderham M, et al. Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. Lancet. 2017;389:2287–2303.
   PubMed Web of Science ®Google Scholar
• Guttman-Yassky E, Bissonnette R, Ungar B, et al. Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. J Allergy Clin Immunol. 2019;143:155–172.
   PubMed Web of Science ®Google Scholar
• Beck JA, Thaci D, Hamilton JD, et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med. 2014;371:130–139.
   PubMed Web of Science ®Google Scholar
• Wang F-P, Tang X-J, Wei C-Q, et al. Dupilumab treatment in moderate-to-severe atopic dermatitis: a systematic review and meta-analysis. J Dermatol Sci. 2018;90:190–198.
   PubMed Web of Science ®Google Scholar
• Deleuran M, Thaci D, Beck LA, et al. Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. J Am Acad Dermatol. 2020;82:377–388.
   PubMed Web of Science ®Google Scholar
• Worm M, Simpson EL, Thaci D, et al. Efficacy and safety of multiple dupilumab dose regimens after initial successful treatment in patients with atopic dermatitis: a randomized clinical trial. JAMA Dermatol. 2020;156:131–143.
   PubMed Web of Science ®Google Scholar
• Beck LA, Thaci D, Deleuran M, et al. Dupilumab provides favorable safety and sustained efficacy for up to 3 years in an open-label study of adults with moderate-to-severe atopic dermatitis. Am J Clin Dermatol. 2020;21:567–577.
   PubMed Web of Science ®Google Scholar
• Thaci D, Simpson EL, Beck LA, et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet. 2016;387:40–52.
   PubMed Web of Science ®Google Scholar
• Zimmermann M, Rind D, Chapman R, et al. Economic evaluation of dupilumab for moderate-to-severe atopic dermatitis: a cost-utility analysis. J Drug Dermatol. 2018;17:750–756.
   PubMed Web of Science ®Google Scholar
• Ivert LU, Wahlgren C-F, Ivert L, et al. Eye complications during dupilumab treatment for severe atopic dermatitis. Acta Derm Venereol. 2019;99:375–378.
   PubMed Web of Science ®Google Scholar
• Faiz S, Giovannelli J, Podevin C, et al. Effectiveness and safety of dupilumab for the treatment of atopic dermatitis in a real-life French multicenter adult cohort. J Am Acad Dermatol. 2019;81:143–151.
   PubMed Web of Science ®Google Scholar
• Treister AD, Kraff-Cooper C, Lio PA. Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis. JAMA Dermatol. 2018;154:1208–1211.
   PubMed Web of Science ®Google Scholar
• Popiela MZ, Barbara R, Turnbull AMJ, et al. Dupilumab-associated ocular surface disease: presentation, management and long-term sequelae. Eye. 2021;35:3277–3284.
   PubMed Web of Science ®Google Scholar
• Eichenfield LF, Bieber T, Beck LA, et al. Infections in dupilumab clinical trials in atopic dermatitis: a comprehensive pooled analysis. Am J Clin Dermatol. 2019;20:443–456.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Beck LA, Blauvelt A, et al. Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). Br J Dermatol. 2020;182:1120–1135.
   PubMed Web of Science ®Google Scholar
• Wollenberg A, Howell Md, Guttman-Yassky E, et al. Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. J Allergy CLin Immunol. 2019;143:135–141.
   PubMed Web of Science ®Google Scholar
• Tollenaere MAX, Litman T, Moebus L, et al. Skin barrier and inflammation genes associated with atopic dermatitis are regulated by interleukin-13 and modulated by tralokinumab in vitro. Acta Derm Venereol. 2021;101(4):adv00447.
   PubMedGoogle Scholar
• Wollenberg A, Blauvelt A, Guttman-Yassky E, et al. Tralokinumab for moderate-to-severe atopic dermatitis: results from two 52-week, randomized, double-blind, multicentre, placebo-controlled phase III trials (ECZTRA 1 and ECZTRA 2). Br J Dermatol. 2021;184:437–449.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Toth D, Bieber T, et al. Tralokinumab plus topical corticosteroids for the treatment of moderate-to-severe atopic dermatitis: results from the double-blind, randomized, multicentre, placebo-controlled phase III ECZTRA 3 trial. Br J Dermatol. 2021;184:450–463.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Guttman-Yassku E, Gooderham M, et al. Health-related quality of life with tralokinumab in moderate-to-severe atopic dermatitis: a phase 2b randomized study. Ann Allergy Asthma Immunol. 2020;S1081-1206(20):31242–31244.
   Google Scholar
• Merola JF, Bagel J, Almgren P, et al. Tralokinumab does not impact vaccine-induced immune responses: results from a 30-week, randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. J Am Acad Dermatol. 2021;S0190-9622(21): 00577–6.
   Google Scholar
• Morra DE, Drucker AM. Tralokinumab for atopic dermatitis: a promising new therapy. Br J Dermatol. 2021;184:386–387.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Matsumura T, Komazaki H, et al. Nemolizumab-JP01 Study group. Trial of nemolizumab and topical agents for atopic dermatitis with pruritus. N Engl J Med. 2020;383:141–150.
   PubMed Web of Science ®Google Scholar
• Silverberg J, Pinter A, Pulka G, et al. Phase 2B randomized study of nemolizumab in adults with moderate-to-severe atopic dermatitis and severe pruritus. J Allergy Clin Immunol. 2020;145:173–182.
   PubMed Web of Science ®Google Scholar
• Silverberg JI, Pinter A, Alavi A, et al. Nemolizumab is associated with a rapid improvement in atopic dermatitis signs and symptoms: subpopulation (EASI ≥ 16) analysis of randomized phase 2B study. J Eur Acad Dermatol Venereol. 2021 Mar 12. DOI:https://doi.org/10.1111/jdv.17218
   Google Scholar
• Mihara R, Kabashima K, Furue M, et al. Nemolizumab in moderate to severe atopic dermatitis: an exploratory analysis of work productivity and activity impairment in a randomized phase II study. J Dermatol. 2019;46:662–671.
   PubMed Web of Science ®Google Scholar
• Kabashima K, Furue M, Hanifin JM, et al. Nemolizumab in patients with moderate-to-severe atopic dermatitis: randomized, phase II, long-term extension study. J Allergy Clin Immunol. 2018;142:1121–1130.
   PubMed Web of Science ®Google Scholar
• Xiao X, Lin L, Zhu C, et al. Efficacy and safety of nemolizumab for treatment of adult atopic dermatitis: a meta-analysis of randomized clinical trials. J Investig Allergol Clin Immunol. 2021;31:190–192.
   PubMed Web of Science ®Google Scholar
• Fala L. Nucala (Mepolizumab): first IL-5 antagonist monoclonal antibody FDA approved for maintenance treatment of patients with severe asthma. Am Health Drug Benefits. 2016;9(Spec Feature):106–110.
   PubMedGoogle Scholar
• Nazik H, Mulayim MK, Ozturk P. Omalizumab usage in chronic urticaria and atopic dermatitis: data from South-East province of Turkey. Postepy Dermatol Alergol. 2019;36:734–738.
   PubMed Web of Science ®Google Scholar
• Holm JG, Thompsen SF. Omalizumab for atopic dermatitis: evidence for and against its use. G Ital Dermatol Venereol. 2019;154:480–487.
   PubMed Web of Science ®Google Scholar
• Velling P, Skowasch D, Pabst S, et al. Improvement of quality of life in patients with concomitant allergic asthma and atopic dermatitis: one year follow-up of omalizumab therapy. Eur J Med Res. 2011;16:407–410.
   PubMed Web of Science ®Google Scholar
• Sheinkopf LE, Rafi AW, Do LT, et al. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc. 2008;29:530–537.
   PubMed Web of Science ®Google Scholar
• F-a MMC, Leis-Dosil V, Alfageme-Roldan F, et al. Omalizumab for the treatment of atopic dermatitis. Actas Dermosifiligr. 2012;103:624–628.
   PubMedGoogle Scholar
• Sormioli S, Matucci A, Dies L, et al. Rapid clinical improvement of atopic dermatitis in an omalizumab treated patient. Clin Mol Allergy. 2019;17:5.
   PubMedGoogle Scholar
• Sirufo MM, De Martinis M. Omalizumab an effective and safe alternative therapy in severe refractory atopic dermatitis: a case report. Medicine (Baltimore). 2018;97(24):e10897.
   PubMed Web of Science ®Google Scholar
• Iannelli M, Caminiti L, Vaccaro M, et al. Omalizumab for treatment of refractory severe atopic dermatitis. A pediatric perspective. Dermatol Ther. 2020;33:e13519.
   PubMed Web of Science ®Google Scholar
• Holm JG, Agner T, Sand C, et al. Omalizumab for atopic dermatitis: Case series and a systematic review of the literature. Int J Dermatol. 2017;56:18–26.
   PubMed Web of Science ®Google Scholar
• Chan S, Cornelius V, Cro S, et al. Treatment effect of omalizumab on severe pediatric atopic dermatitis: the adapt randomized clinical trial. JAMA Pediatr. 2019;174:29–37.
   Web of Science ®Google Scholar
• Wu AC. Omalizumab for atopic dermatitis: Overtreatment or lifesaver? JAMA Pediatr. 2019 Nov 25. DOI:https://doi.org/10.1001/jamapediatrics.2019.4509
   Google Scholar
• Garcia M, Duran-Crane A, Chapman E, et al. Omalizumab as an adjuvant therapy for treating severe atopic dermatitis in children. A series of cases. Rev Alerg Mex. 2019;66:282–291.
   PubMedGoogle Scholar
• Oldhoff JM, Darsow U, Wefel T, et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy. 2005;60:603–606.
   Web of Science ®Google Scholar
• Oldhoff JM, Darsow U, Werfel T, et al. No effect of anti-interleukin-5 therapy (mepolizumab) on the atopy patch test in atopic dermatitis patients. Int Arch Allergy Immunol. 2006;141:290–294.
   PubMed Web of Science ®Google Scholar
• Kang EG, Narayana PK, Pouliquen IJ, et al. Efficacy and safety of mepolizumab administered subcutaneously for moderate to severe atopic dermatitis. Allergy. 2020;75:950–953.
   PubMed Web of Science ®Google Scholar
• Benson JM, Peritt D, Scallon BJ, et al. Discovery and mechanism of ustekinumab: a human monoclonal antibody targeting interleukin-12 and interleukin-23 for treatment of immune-mediated disorders. MAbs. 2011;3:535–545.
   PubMed Web of Science ®Google Scholar
• Khattri S, Brunner PM, Garcet S, et al. Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. Exp Dermatol. 2017;26:28–35.
   PubMed Web of Science ®Google Scholar
• Weiss D, Schaschinger M, Ristl R, et al. Ustekinumab treatment in severe atopic dermatitis: Down-regulation of T-helper 2/22 expression. J Am Acad Dermatol. 2017;76:91–97.
   PubMed Web of Science ®Google Scholar
• Saeki H, Kabashima K, Tokura Y, et al. Efficacy and safety of ustekinumab in Japanese patients with severe atopic dermatitis: a randomized, double-blind, placebo-controlled, phase II study. Br J Dermatol. 2017;177:419–427.
   PubMed Web of Science ®Google Scholar
• Samuel RJ, Reynolds NJ. Ustekinumab for severe atopic dermatitis: an important negative study. Br J Dermatol. 2017;177:339–341.
   PubMed Web of Science ®Google Scholar
• Dhonncha NE, Clowry J, Dunphy M, et al. Treatment of severe atopic dermatitis with ustekinumab: a case series of 10 patients. Br J Dermatol. 2017;177:1752–1753.
   PubMed Web of Science ®Google Scholar
• F-a MMC, Roldan FA, Blanco CC, et al. Ustekinumab in the treatment of severe atopic dermatitis: a preliminary report of our experience with 4 patients. Actas Dermosifiliogr. 2014;105:312–313.
   PubMedGoogle Scholar
• Shroff A, Guttman-Yassky E. Successful use of ustekinumab therapy in refractory severe atopic dermatitis. JAAD Case Rep. 2014;1:25–26.
   PubMedGoogle Scholar
• Puya R, Alvarez-Lopez M, Velez A, et al. Treatment of severe refractory adult atopic dermatitis with ustekinumab. Int J Dermatol. 2012;51:115–116.
   PubMed Web of Science ®Google Scholar
• Agusti-Mejias A, Messeguer F, Garcia R, et al. Severe refractory atopic dermatitis in an adolescent patient successfully treated with ustekinumab. Ann Dermatol. 2013;25:368–370.
   PubMed Web of Science ®Google Scholar
• Wlodek C, Hewitt H, Kennedy CT. Use of ustekinumab for severe refractory atopic dermatitis in a young teenager. Clin Exp Dermatol. 2016;41:625–627.
   PubMed Web of Science ®Google Scholar
• Samorano LP, Hanifin JM, Simpson EL, et al. Inadequate response to ustekinumab in atopic dermatitis - a report of two patients. J Eur Acad Dermatol Venereol. 2016;30:522–523.
   PubMed Web of Science ®Google Scholar
• Pan Y, Xu L, Qiao J, et al. A systematic review of ustekinumab in the treatment of atopic dermatitis. J Dermatolog Treat. 2018;29:539–541.
   PubMed Web of Science ®Google Scholar
• Ishiuji Y, Umezawa Y, Asahina A, et al. Exacerbation of atopic dermatitis symptoms by ustekinumab in psoriatic patients with elevated serum immunoglobulin E levels: Report of two cases. J Dermatol. 2018;45:732–734.
   PubMed Web of Science ®Google Scholar
• Lis-Swiety A, Skrzypek-Salamon A, Arasiewicz H, et al. Atopic dermatitis exacerbated with ustekinumab in a psoriatic patient with childhood history of atopy. Allergol Int. 2015;64:382–383.
   PubMed Web of Science ®Google Scholar
• Husein-elahmed H, Steinhoff M. Effectiveness of ustekinumab in patients with atopic dermatitis: analysis of real-world evidence. J Dermatolg Treat. Apr 2021;13:1–21.
   Google Scholar
• Simon D, Hösli S, Kostylina G, et al. Anti-CD20 (rituximab) treatment improves atopic eczema. J Allergy Clin Immunol. 2008;121:122–128.
   PubMed Web of Science ®Google Scholar
• Duarte B, Cordeiro A, Paiva-Lopes MJ. Rituximab revisited: successful management of severe childhood atopic dermatitis. Eur J Dermatol. 2018 Dec 10. DOI:https://doi.org/10.1684/ejd.2018.3460
   Google Scholar
• Ponte P, Lopes MJP. Apparent safe use of single dose rituximab for recalcitrant atopic dermatitis in the first trimester of a twin pregnancy. J Am Acad Dermatol. 2010;63:355–356.
   PubMed Web of Science ®Google Scholar